JP2015501840A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015501840A5 JP2015501840A5 JP2014547353A JP2014547353A JP2015501840A5 JP 2015501840 A5 JP2015501840 A5 JP 2015501840A5 JP 2014547353 A JP2014547353 A JP 2014547353A JP 2014547353 A JP2014547353 A JP 2014547353A JP 2015501840 A5 JP2015501840 A5 JP 2015501840A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- seq
- sequence encoding
- subunit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000007523 nucleic acids Chemical group 0.000 claims description 404
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 347
- 239000012634 fragment Substances 0.000 claims description 253
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 claims description 107
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 claims description 107
- 102000014154 Interleukin-12 Subunit p35 Human genes 0.000 claims description 105
- 108010011301 Interleukin-12 Subunit p35 Proteins 0.000 claims description 105
- 102000004169 proteins and genes Human genes 0.000 claims description 76
- 108090000623 proteins and genes Proteins 0.000 claims description 76
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 57
- 108020004707 nucleic acids Proteins 0.000 claims description 57
- 102000039446 nucleic acids Human genes 0.000 claims description 57
- 108091026890 Coding region Proteins 0.000 claims description 36
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 34
- 230000002163 immunogen Effects 0.000 claims description 20
- 239000013612 plasmid Substances 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 230000028993 immune response Effects 0.000 claims description 12
- 201000009182 Chikungunya Diseases 0.000 claims description 6
- 241000710198 Foot-and-mouth disease virus Species 0.000 claims description 6
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 6
- 241000711920 Human orthopneumovirus Species 0.000 claims description 6
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 6
- 241000700647 Variola virus Species 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 6
- 201000004792 malaria Diseases 0.000 claims description 6
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 244000052769 pathogen Species 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 5
- 238000004520 electroporation Methods 0.000 claims description 4
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- -1 SEQ ID NO: 2 amino acids Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 241000700605 Viruses Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569600P | 2011-12-12 | 2011-12-12 | |
| US61/569,600 | 2011-12-12 | ||
| PCT/US2012/069017 WO2013090296A1 (en) | 2011-12-12 | 2012-12-11 | Compositions, comprising improved il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018084090A Division JP6803354B2 (ja) | 2011-12-12 | 2018-04-25 | 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015501840A JP2015501840A (ja) | 2015-01-19 |
| JP2015501840A5 true JP2015501840A5 (enExample) | 2016-01-21 |
| JP6333730B2 JP6333730B2 (ja) | 2018-05-30 |
Family
ID=48613120
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547353A Active JP6333730B2 (ja) | 2011-12-12 | 2012-12-11 | 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2018084090A Active JP6803354B2 (ja) | 2011-12-12 | 2018-04-25 | 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2020198052A Active JP7129106B2 (ja) | 2011-12-12 | 2020-11-30 | 改善されたｉｌ－１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2022129334A Withdrawn JP2022160704A (ja) | 2011-12-12 | 2022-08-15 | 改善されたｉｌ－１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2024109421A Pending JP2024138373A (ja) | 2011-12-12 | 2024-07-08 | 改善されたｉｌ－１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018084090A Active JP6803354B2 (ja) | 2011-12-12 | 2018-04-25 | 改善されたｉｌ−１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2020198052A Active JP7129106B2 (ja) | 2011-12-12 | 2020-11-30 | 改善されたｉｌ－１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2022129334A Withdrawn JP2022160704A (ja) | 2011-12-12 | 2022-08-15 | 改善されたｉｌ－１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
| JP2024109421A Pending JP2024138373A (ja) | 2011-12-12 | 2024-07-08 | 改善されたｉｌ－１２遺伝子構築物を含む組成物、及びそれを用いたワクチン、免疫治療剤及び方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9272024B2 (enExample) |
| EP (2) | EP2791157A4 (enExample) |
| JP (5) | JP6333730B2 (enExample) |
| KR (5) | KR20240096837A (enExample) |
| CN (1) | CN104245719B (enExample) |
| AU (1) | AU2012352457B2 (enExample) |
| BR (1) | BR112014014078A2 (enExample) |
| CA (1) | CA2858893A1 (enExample) |
| EA (1) | EA026926B1 (enExample) |
| MX (2) | MX354986B (enExample) |
| WO (1) | WO2013090296A1 (enExample) |
| ZA (1) | ZA201404199B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX354986B (es) * | 2011-12-12 | 2018-03-28 | Univ Pennsylvania | Composiciones que comprenden construcciones geneticas y vacunas de il-12 mejoradas, agentes inmunoterapeuticos y metodos para su uso. |
| US9669091B2 (en) | 2013-03-15 | 2017-06-06 | Inovio Pharmaceuticals, Inc. | Vaccines having an antigen and interleukin-23 as an adjuvant |
| JP2018504403A (ja) * | 2015-01-09 | 2018-02-15 | オンコセック メディカル インコーポレイテッド | 悪性腫瘍の治療に対する方法 |
| JP6912384B2 (ja) | 2015-04-22 | 2021-08-04 | キュアバック アーゲー | 癌疾患の処置のための、ｒｎａ含有組成物 |
| DK3458083T5 (da) | 2016-05-18 | 2024-10-21 | Modernatx Inc | Polynukleotider, der koder for interleukin-12 (il12), og anvendelser heraf |
| US10888594B2 (en) | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
| US20190336552A1 (en) | 2016-05-30 | 2019-11-07 | Astellas Pharma Inc. | Genetically engineered vaccinia viruses |
| CN106520779A (zh) * | 2016-11-09 | 2017-03-22 | 华南农业大学 | 一种通过密码子优化鸡il‑2基因提高鸡的il‑2蛋白表达效率的方法 |
| CA3063723A1 (en) | 2017-05-18 | 2018-11-22 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof |
| US11638730B2 (en) | 2018-09-26 | 2023-05-02 | Astellas Pharma Inc. | Cancer therapy by combination use of oncolytic vaccinia virus and immune checkpoint inhibitor, and pharmaceutical composition and combination medicine for use in the cancer therapy |
| SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
| KR102524247B1 (ko) | 2018-12-21 | 2023-04-21 | 가톨릭대학교 산학협력단 | p40-EBI3의 복합체 및 이의 용도 |
| TW202124722A (zh) | 2019-09-18 | 2021-07-01 | 美商英特佳樂帝克醫療公司 | 合成dna載體及其使用方法 |
| CN115916233A (zh) | 2019-10-03 | 2023-04-04 | Xencor股份有限公司 | 靶向IL-12异源二聚体Fc融合蛋白 |
| MX2022004836A (es) * | 2019-10-24 | 2022-07-19 | Inovio Pharmaceuticals Inc | Vacunas mejoradas para la papilomatosis respiratoria recurrente y métodos para su uso. |
| CN110777115B (zh) * | 2019-11-21 | 2020-08-21 | 北京启辰生生物科技有限公司 | 用于促进辅助T细胞产生TNF-α细胞因子的工程化DC细胞及方法 |
| KR20230096959A (ko) | 2020-07-20 | 2023-06-30 | 데카 바이오사이언시즈, 인크. | Il-10을 포함하는 이중 시토카인 융합 단백질 |
| MX2024007270A (es) * | 2021-12-13 | 2024-06-26 | Deka Biosciences Inc | Proteinas de fusion de citocinas duales que comprenden citocinas de multiples subunidades. |
| CA3241210A1 (en) * | 2021-12-17 | 2023-06-22 | Omid Veiseh | Encapsulated cells expressing il-12 and uses thereof |
| CN116621965A (zh) * | 2022-05-06 | 2023-08-22 | 珠海丽凡达生物技术有限公司 | 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用 |
| WO2023229013A1 (ja) * | 2022-05-27 | 2023-11-30 | 北京天一方生物科技▲発▼展有限公司 | ＩＬ－１２ｐ７０を恒常的に産生する増殖性ミエロイド細胞の製造方法 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
| US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
| GB8508845D0 (en) | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
| US5223424A (en) | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
| US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
| US5242829A (en) | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
| US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
| IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
| US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
| US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
| US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| AU625584B2 (en) | 1989-03-08 | 1992-07-16 | Health Research Inc. | Recombinant poxvirus host selection system |
| JP3004049B2 (ja) | 1989-03-31 | 2000-01-31 | ワシントン ユニバーシティー | 病原性のないｐｈｏＰ型微生物を含有するワクチン |
| EP0431668B1 (en) | 1989-12-04 | 1995-02-15 | Akzo Nobel N.V. | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof |
| US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
| US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
| US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| US5273525A (en) | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| WO1994016737A1 (en) | 1993-01-26 | 1994-08-04 | Weiner David B | Compositions and methods for delivery of genetic material |
| US5571515A (en) | 1994-04-18 | 1996-11-05 | The Wistar Institute Of Anatomy & Biology | Compositions and methods for use of IL-12 as an adjuvant |
| GB9505784D0 (en) * | 1995-03-22 | 1995-05-10 | Lynxvale Ltd | Anti-tumour treatment |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| AU4908197A (en) * | 1996-10-18 | 1998-05-15 | Valentis, Inc. | Gene expression and delivery systems and uses |
| US6261281B1 (en) | 1997-04-03 | 2001-07-17 | Electrofect As | Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells |
| AU733628B2 (en) | 1997-04-03 | 2001-05-17 | Electrofect As | Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle |
| JP2002507985A (ja) | 1997-06-30 | 2002-03-12 | ローヌ−プーラン・ロレ・エス・アー | 横紋筋に核酸を導入する改良法およびその組合せ |
| AU3000399A (en) * | 1998-03-19 | 1999-10-11 | Valentis, Inc. | Interferon alpha plasmids and delivery systems, and methods of making and using the same |
| CA2337652C (en) | 1998-07-13 | 2013-03-26 | Genetronics, Inc. | Skin and muscle-targeted gene therapy by pulsed electrical field |
| US20030181405A1 (en) * | 1999-03-12 | 2003-09-25 | Nordstrom Jeffrey L. | Interferon alpha plasmids and delivery systems, and methods of making and using the same |
| JP3543326B2 (ja) | 2001-08-30 | 2004-07-14 | ソニー株式会社 | 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム |
| US8209006B2 (en) | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US7328064B2 (en) | 2002-07-04 | 2008-02-05 | Inovio As | Electroporation device and injection apparatus |
| TWI290174B (en) | 2002-11-04 | 2007-11-21 | Advisys Inc | Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells |
| CA2527869A1 (en) | 2003-05-30 | 2004-12-23 | University Of South Florida | Method for the treatment of malignancies |
| DK1628749T3 (da) | 2003-05-30 | 2019-09-16 | Vgxi Inc | Anordninger og fremgangsmåder til biomateriel produktion |
| WO2007084364A2 (en) * | 2006-01-13 | 2007-07-26 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health | Improved il-12 for expression in mammalian cells |
| WO2008089144A2 (en) * | 2007-01-12 | 2008-07-24 | The Government Of The United States, As Represented By The Secretary Of Health And Human Services | Improved dna vaccination protocols |
| AU2010241864B2 (en) * | 2009-04-30 | 2014-02-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible interleukin-12 |
| MX354986B (es) | 2011-12-12 | 2018-03-28 | Univ Pennsylvania | Composiciones que comprenden construcciones geneticas y vacunas de il-12 mejoradas, agentes inmunoterapeuticos y metodos para su uso. |
| GB2504774A (en) | 2012-08-10 | 2014-02-12 | Munster Simms Eng Ltd | Diaphragm pump with integral motor housing and rear pump housing |
| TWI548337B (zh) | 2015-10-16 | 2016-09-01 | 技嘉科技股份有限公司 | 散熱模組、顯示卡組件及電子裝置 |
-
2012
- 2012-12-11 MX MX2014006987A patent/MX354986B/es active IP Right Grant
- 2012-12-11 US US14/365,086 patent/US9272024B2/en active Active
- 2012-12-11 EP EP12857726.9A patent/EP2791157A4/en not_active Ceased
- 2012-12-11 AU AU2012352457A patent/AU2012352457B2/en active Active
- 2012-12-11 BR BR112014014078-2A patent/BR112014014078A2/pt not_active Application Discontinuation
- 2012-12-11 JP JP2014547353A patent/JP6333730B2/ja active Active
- 2012-12-11 KR KR1020247019230A patent/KR20240096837A/ko active Pending
- 2012-12-11 CN CN201280069473.6A patent/CN104245719B/zh active Active
- 2012-12-11 KR KR1020227031904A patent/KR102674807B1/ko active Active
- 2012-12-11 KR KR1020217021512A patent/KR102445129B1/ko active Active
- 2012-12-11 CA CA2858893A patent/CA2858893A1/en active Pending
- 2012-12-11 EP EP17201202.3A patent/EP3336096A1/en active Pending
- 2012-12-11 KR KR1020147019094A patent/KR102101819B1/ko active Active
- 2012-12-11 EA EA201491171A patent/EA026926B1/ru not_active IP Right Cessation
- 2012-12-11 KR KR1020207010487A patent/KR102277469B1/ko active Active
- 2012-12-11 WO PCT/US2012/069017 patent/WO2013090296A1/en not_active Ceased
-
2014
- 2014-06-06 ZA ZA2014/04199A patent/ZA201404199B/en unknown
- 2014-06-11 MX MX2020001385A patent/MX2020001385A/es unknown
-
2016
- 2016-02-26 US US15/055,002 patent/US9981036B2/en active Active
-
2018
- 2018-04-25 JP JP2018084090A patent/JP6803354B2/ja active Active
- 2018-05-09 US US15/974,982 patent/US11241496B2/en active Active
-
2020
- 2020-11-30 JP JP2020198052A patent/JP7129106B2/ja active Active
-
2021
- 2021-12-28 US US17/563,392 patent/US20220193230A1/en active Pending
-
2022
- 2022-08-15 JP JP2022129334A patent/JP2022160704A/ja not_active Withdrawn
-
2024
- 2024-07-08 JP JP2024109421A patent/JP2024138373A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015501840A5 (enExample) | ||
| JP6957580B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| JP2015501656A5 (enExample) | ||
| JP2014507146A5 (enExample) | ||
| JP2009544333A5 (enExample) | ||
| FI3872085T3 (fi) | Esimuotoiset virussekvenssit ja niiden käytöt | |
| JP2014502156A5 (enExample) | ||
| EP3199545A3 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
| JP2019506175A5 (enExample) | ||
| BRPI0417509A (pt) | molécula de proteìna quimérica de núcleo de vìrus da hepatite b (hbc) recombinante, partìculas, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, e, célula hospedeira | |
| JP2012515557A5 (enExample) | ||
| JP2017532966A5 (enExample) | ||
| JP2019530462A5 (enExample) | ||
| RU2015135890A (ru) | Композиция вакцины | |
| JP2009540801A5 (enExample) | ||
| EA202090738A1 (ru) | Способ безопасного индуцирования иммунитета против rsv | |
| JP2016533332A5 (enExample) | ||
| JP2015524422A5 (enExample) | ||
| JP2015506705A5 (enExample) | ||
| BR112014018884A2 (pt) | antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b | |
| JP2014519817A5 (enExample) | ||
| WO2006037038B1 (en) | Optimized vaccines to provide protection against ebola and other viruses | |
| WO2014205579A4 (en) | Modified matrix proteins of vesicular stomatitis virus | |
| JP2019505567A5 (enExample) | ||
| JP2010532656A5 (enExample) |